IQ-AI finances Phase I trial evaluating Gallium Maltolate in treatment of Glioblastoma Multiforme Imaging Biometrics’ IB Clinic software used to assess performance IQ-AI Limited (LON:IQAI) — IQ-AI commits to funding a phase I clinical trial to evaluate the safety and efficacy of Gallium Maltolate (GaM) in the treatment of Glioblastoma Multiforme (GBM). Its Imaging Biometrics
IQ-AI’s Imaging Biometrics’ IB Neuro brain tumor software named part of standard imaging protocol IQ-AI Limited (LON:IQAI) — The investment firm explains how IB’s brain tumour imaging software benefits patients and their treatment teams, and why IB Neuro was solely included as the image post-processing component of the new standardised imaging protocol for brain tumours.
IQ-AI’s Imaging Biometrics Appoints South Korean Distributor as it Receives Regulatory Certification IQ-AI Limited (LON:IQAI) — The investment firm said that IB’s distributor would sell its full range of imaging products relating to brain tumour detection in the country.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.